Irreversible Inhibitor Dacomitinib CAS: 1110813-31-4 Weißes Puder
Überlegenheit
Zhongshan Latterson Biotechnology Co., GmbH., ist ein umfassendes Pharmaunternehmen, die sich auf biopharmazeutische Technologie spezialisiert haben 7 Jahre. Das Unternehmen befindet sich in der Stadt Zhongshan, Provinz Guangdong , China.
Unsere Fabrik umfasst eine Fläche von 33500 Quadratmeter, mit sauberer Umgebung und schönem Layout. Es gibt mehrere große oder mittlere Werkstätten und ein QS- und Forschungszentrum mit fortschrittlicher Ausrüstung. Derzeit, Unsere Hauptprodukte sind anabole Steroide, Peptid-Serie, Lokalanästhesie-Serie. Unsere Produkte erreichen den fortgeschrittenen Standard des heimischen Marktes, viele davon erreichen den internationalen Standard, Zertifikate enthalten: KOSCHER , ISO 9001:2008 , GMP , SGS.
Grundinformation:
Produktname: Dacomitinib
Synonyme: Dacomitinib;PF-00299804-03;PF-00299804;DacoMitinib (PF-00299804);DacoMitinib,PF299804;DacoMitinib (PF299804,PF-00299804);DacoMitinib (PF299804, PF299);(2E)-N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]-4-(1-piperidinyl)-2-butenamide Dacomitinib (PF299804, PF299)
FALL: 1110813-31-4
MF: C24H25ClFN5O2
MW: 469.9390032
Dichte: 1.344
ARTIKEL |
SPEZIFIKATION |
TESTRESULTS |
Aussehen |
Off-white or white powder |
Entspricht |
Identifizierung |
Testgegenstände,NMR;LC-MS |
Entspricht |
Verwandte Substanzen |
Individual impurity≤0.5% |
0.09% |
Gesamtverunreinigungen≤1,0% |
0.20% |
Trocknungsverlust |
≤0,5 % |
0.3% |
Glührückstand |
≤0,1 % |
0.04% |
Schwermetalle |
≤10ppm |
Entspricht |
Assay |
≥98.0 % |
99.1% |
Beschreibung:
Dacomitinib is a selective and irreversible inhibitor of EGFR. It is a drug candidate for the treatment of non-small cell lung carcinoma. It is current under the Phase III clinical trials. It also shows potential for the treatment of HER-2 amplified breast cancer cells lines that are resistant to trastuzumab and lapatinib.
Biological activity:
Dacomitibib (Dacomitinib, PF299804) is an effective and irreversible pan-ErbB inhibitor that is most effective in EGFR, with an IC50 of 6 nM. It is also highly effective in NSCLCs that carries EGFR or ERBB2 mutants (against Gefitinib) and EGFR T790M mutant. Phase 2. Dacomitinib is taken orally once-daily. It is an irreversible inhibitor of HER-1 (EGFR), HER-2 and HER-4 tyrosine kinases. Dacomitinib targets multiple receptors of the HER pathway, whereas currently marketed HER-1 (EGFR) inhibitors for non-small cell lung cancer (NSCLC) target only one receptor in this pathway,developed by Pfizer.
Clinical Study Dacomitinib has advanced to several Phase III clinical trials. The results of the first trials were disappointing, with a failure to meet the study goals, Additional Phase III trials are ongoing. Clinical evaluation of dacomitinib is ongoing in a number of clinical trials in patients with advanced NSCLC across lines of therapies and a range of histologies and molecular subtypes, such as EGFR and KRAS status.
Zusätzlich, there is an ongoing clinical trial evaluating dacomitinib in recurrent and/or metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN).
Verwendet:
PF299804 is a potent, irreversible pan-ErbB inhibitor against ErbB1, ErbB2 and ErbB4 with IC50 of 6 nM, 45.7 nM and 73.7 nM, beziehungsweise.
Fettverbrennung(Rohpulver) |
T3 (Liothyronine Sodium) |
T4 (L-Thyroxine / L-Thyroxine Sodium salt) |
L-Carnitine |
Theobromine |
Synephrine |
Synephrin HCL |
Rimonabant |
Lorcaserin HCl |
CLA (Conjugated Linoleic Acid) |
Orlistat |
Calcium Pyruvate |
DMAA (1,3-Dimethylpentylamine HCL) |
L-Citrulline |
|
Andere Hot-Sale-Produkte (Rohpulver) |
TUDCA (Tauroursodesoxycholsäure) |
GBL (Y-Butyrolacton) |
1,4-Butandiol |
Minoxidil |
Melatonin |
Tretinoin |
Sunifiram |
Pregabalin |
Phenacetin |
Paracetamol |
Levamisol HCL |
Pirfenidon |
Epinephrin HCL |
Pregnenolon-Rohpulver CAS |
Dextromethorphan-Hydrobromid-Monohydrat |
Argireline |
SNAP-8 1 mg/Fläschchen |
Theophyllin |
Diclofenac-Natrium |
Tianeptin-Natriumsalz |
Noopept |
Beta-Nicotinamid-Mononukleotid |
Clobetasolpropionat |
Polyethylenglykol(ANBINDUNG) |
Ketoprofen |
1,3-Dimethylbutylaminhydrochlorid |
Polyvinylpyrrolidon |
Baricitinib |
Diprophyllin |
Aminophyllin |
Tianeptin |
Tianeptinsulfatsulfat |